PDF: Wiebe Surgery for TLE
(2001)Objective
To compare anterior temporal lobectomy with optimized medical therapy in drug-resistant temporal lobe epilepsy.
Study Summary
• Complete seizure freedom (including auras) was 38% (surgery) vs 3% (medical)
• Quality of life (QOLIE-89) was significantly higher after surgery; surgical complications occurred in ~10% and 1 medical patient died of SUDEP
Intervention
Standardized anterior temporal lobectomy vs optimized medical (AED) therapy; N=80
Inclusion Criteria
Age 16-69 years, drug-resistant temporal lobe epilepsy (failed ≥2 AEDs), seizures >1 year, concordant EEG/MRI localization, candidate for ATL.
Study Design
Arms: Anterior Temporal Lobectomy vs Optimized Medical Therapy (control)
Patients per Arm: Surgery: 40, Medical: 40
Outcome
• Complete seizure freedom: 38% vs 3%
• QOLIE-89 significantly better with surgery (p<0.001)
• Surgical complications ~10%; 1 SUDEP death in the medical arm
Bottom Line
In this first-ever RCT of epilepsy surgery, anterior temporal lobectomy was overwhelmingly superior to medical therapy, with 58% vs 8% achieving freedom from seizures impairing awareness at 1 year (p<0.001, NNT=2). Surgery also significantly improved quality of life, disability scores, and complete seizure freedom (38% vs 3%). Surgical complications occurred in 10% (verbal memory decline, visual field cut, wound infection) with no operative mortality.
Major Points
- Surgery superior: seizure-free at 1 year 58% vs 8% (P<0.001). NNT=2.
- Quality of life (QOLIE-89) significantly better: surgery 75.7 vs medical 65.2 (P<0.001).
- 80 patients randomized (40 surgery, 40 medical). Single center (London, Canada).
- Surgery: anterior temporal lobectomy (standardized). Medical: optimized AED management.
- Verbal memory decline in dominant surgery: 20% had significant decline on neuropsych testing.
- 4 surgical complications: 1 wound infection, 1 CSF leak, 1 visual field defect, 1 depression.
- Only RCT of epilepsy surgery vs medical management — remains definitive evidence.
- Landmark trial establishing Class I evidence for surgery in drug-resistant TLE.
- Published NEJM 2001. Led to guideline recommendations for early surgical referral.
- Mean duration of epilepsy: ~20 years — argues for earlier referral than current practice.
Study Design
- Study Type
- Prospective, randomized, controlled, parallel-group trial with blinded outcome assessment
- Randomization
- Yes
- Blinding
- Outcome assessors blinded; patients and surgeons unblinded
- Sample Size
- 80
- Follow-up
- 1 year
- Centers
- 1
- Countries
- Canada
Primary Outcome
Definition: Freedom from seizures impairing awareness at 1 year
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| Medical: 3/40 (8%) seizure-free | Surgery: 23/40 (58%) seizure-free | - | <0.001 |
Limitations & Criticisms
- Single-center study: may not generalize to all surgical centers and teams
- Short follow-up (1 year only): does not capture long-term seizure recurrence (30-50% by 10 years in observational data)
- Small sample size (n=80) limits power for subgroup analyses
- Waiting-list control design: medical group knew they would receive surgery later, potential nocebo effect
- Cannot blind patients or surgeons: expectation bias possible
- Predominantly mesial temporal sclerosis population -- may not generalize to other TLE pathologies
- Limited ethnic and socioeconomic diversity
Citation
Wiebe S et al. N Engl J Med. 2001;345(5):311-318. DOI: 10.1056/NEJM200108023450501